Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LFCR NASDAQ:SPRY NASDAQ:SYRE NASDAQ:UPB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLFCRLifecore Biomedical$6.74-1.6%$7.41$4.33▼$8.85$256.64M0.62217,392 shs129,162 shsSPRYARS Pharmaceuticals$10.33+0.6%$12.59$9.34▼$18.90$1.01B0.842.84 million shs1.94 million shsSYRESpyre Therapeutics$16.02-3.9%$16.29$10.91▼$40.26$1.01B2.9681,165 shs439,743 shsUPBUpstream Bio$18.67-1.6%$17.42$5.14▼$29.46$1.02BN/A462,482 shs190,145 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLFCRLifecore Biomedical-1.61%-8.42%-10.49%-17.30%+32.42%SPRYARS Pharmaceuticals+0.58%+2.79%+2.58%-42.29%-24.38%SYRESpyre Therapeutics-3.90%-4.42%-5.76%-3.20%-41.75%UPBUpstream Bio-1.58%-0.74%-6.51%+59.57%+1,866,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLFCRLifecore Biomedical$6.74-1.6%$7.41$4.33▼$8.85$256.64M0.62217,392 shs129,162 shsSPRYARS Pharmaceuticals$10.33+0.6%$12.59$9.34▼$18.90$1.01B0.842.84 million shs1.94 million shsSYRESpyre Therapeutics$16.02-3.9%$16.29$10.91▼$40.26$1.01B2.9681,165 shs439,743 shsUPBUpstream Bio$18.67-1.6%$17.42$5.14▼$29.46$1.02BN/A462,482 shs190,145 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLFCRLifecore Biomedical-1.61%-8.42%-10.49%-17.30%+32.42%SPRYARS Pharmaceuticals+0.58%+2.79%+2.58%-42.29%-24.38%SYRESpyre Therapeutics-3.90%-4.42%-5.76%-3.20%-41.75%UPBUpstream Bio-1.58%-0.74%-6.51%+59.57%+1,866,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLFCRLifecore Biomedical 2.20Hold$8.0018.69% UpsideSPRYARS Pharmaceuticals 2.86Moderate Buy$33.80227.20% UpsideSYRESpyre Therapeutics 3.00Buy$54.29238.86% UpsideUPBUpstream Bio 2.60Moderate Buy$56.50202.62% UpsideCurrent Analyst Ratings BreakdownLatest LFCR, UPB, SYRE, and SPRY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025LFCRLifecore BiomedicalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/27/2025SPRYARS PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025SYRESpyre TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025UPBUpstream BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/26/2025SPRYARS PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$32.009/26/2025SYRESpyre TherapeuticsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$43.009/16/2025SYRESpyre TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$70.009/4/2025SPRYARS PharmaceuticalsRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.009/3/2025LFCRLifecore BiomedicalKeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSector Weight8/6/2025SYRESpyre TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$65.00(Data available from 10/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLFCRLifecore Biomedical$128.87M1.96N/AN/A$0.04 per share168.50SPRYARS Pharmaceuticals$89.15M11.45$0.01 per share1,212.76$2.64 per share3.91SYRESpyre Therapeutics$890K1,087.20N/AN/A$7.04 per share2.28UPBUpstream Bio$2.37M424.68N/AN/A$8.77 per share2.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLFCRLifecore Biomedical-$38.72M-$1.31N/AN/AN/A-31.70%-846.51%-13.03%10/13/2025 (Estimated)SPRYARS Pharmaceuticals$8M-$0.49N/AN/AN/A-42.74%-21.85%-15.88%11/12/2025 (Estimated)SYRESpyre Therapeutics-$208.02M-$3.40N/AN/AN/AN/A-71.30%-38.69%11/6/2025 (Estimated)UPBUpstream Bio-$62.81MN/A0.00N/AN/A-3,836.58%-35.90%-26.26%11/6/2025 (Estimated)Latest LFCR, UPB, SYRE, and SPRY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/13/2025Q1 2026LFCRLifecore Biomedical-$0.29N/AN/AN/A$26.68 millionN/A8/13/2025Q2 2025SPRYARS Pharmaceuticals-$0.41-$0.46-$0.05-$0.46$12.92 million$15.72 million8/7/2025Q4 2025LFCRLifecore Biomedical-$0.09-$0.10-$0.01-$0.06$35.36 million$36.44 million8/6/2025Q2 2025UPBUpstream Bio-$0.61-$0.74-$0.13-$0.74$0.32 million$0.94 million8/5/2025Q2 2025SYRESpyre Therapeutics-$0.73-$0.49+$0.24-$0.49N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLFCRLifecore BiomedicalN/AN/AN/AN/AN/ASPRYARS PharmaceuticalsN/AN/AN/AN/AN/ASYRESpyre TherapeuticsN/AN/AN/AN/AN/AUPBUpstream BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLFCRLifecore Biomedical113.762.841.77SPRYARS Pharmaceuticals0.376.175.98SYRESpyre TherapeuticsN/A6.496.49UPBUpstream BioN/A38.2738.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLFCRLifecore Biomedical83.36%SPRYARS Pharmaceuticals68.16%SYRESpyre Therapeutics80.39%UPBUpstream BioN/AInsider OwnershipCompanyInsider OwnershipLFCRLifecore Biomedical31.98%SPRYARS Pharmaceuticals33.50%SYRESpyre Therapeutics6.20%UPBUpstream Bio13.56%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLFCRLifecore Biomedical69037.47 million25.48 millionOptionableSPRYARS Pharmaceuticals9098.83 million65.72 millionOptionableSYRESpyre Therapeutics7360.40 million56.66 millionOptionableUPBUpstream Bio3853.91 million46.60 millionN/ALFCR, UPB, SYRE, and SPRY HeadlinesRecent News About These CompaniesUpstream Bio management to meet with Piper SandlerOctober 7 at 10:08 PM | msn.comWilliam Blair Sticks to Their Buy Rating for Upstream Bio, Inc. (UPB)October 7 at 2:04 AM | theglobeandmail.comUpstream Bio (UPB): Assessing Valuation as Shares Climb 7% Over the Past WeekOctober 4, 2025 | finance.yahoo.comUpstream Bio, Inc. (NASDAQ:UPB) Receives Consensus Recommendation of "Buy" from BrokeragesOctober 3, 2025 | marketbeat.comUpstream Bio’s verekitug shows prevention of TSLP binding in respiratory diseaseSeptember 30, 2025 | msn.comUpstream Bio (NASDAQ:UPB) Trading 4.2% Higher - Still a Buy?September 30, 2025 | marketbeat.comUpstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug’s Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European ...September 30, 2025 | finance.yahoo.comUpstream Bio, Inc. Presents Data on Verekitug's Mechanism of Action at ERS Congress, Highlighting Its Potential in Treating TSLP-Driven Severe Respiratory DiseasesSeptember 30, 2025 | quiverquant.comQUpstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society CongressSeptember 30, 2025 | globenewswire.comUpstream Bio (NASDAQ:UPB) Shares Down 5.3% - Here's What HappenedSeptember 18, 2025 | marketbeat.comUpstream Bio (NASDAQ:UPB) Trading 5.9% Higher - Still a Buy?September 17, 2025 | marketbeat.comUpstream Bio, Inc. (UPB): A Bull Case TheorySeptember 16, 2025 | msn.comTD Cowen Remains a Buy on Upstream Bio, Inc. (UPB)September 10, 2025 | theglobeandmail.comUpstream Bio Announces Positive Phase 2 Trial ResultsSeptember 9, 2025 | theglobeandmail.comUpstream Bio, Inc. CEO Rand Sutherland to Speak at Stifel 2025 Virtual Immunology and Inflammation ForumSeptember 9, 2025 | quiverquant.comQUpstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation ForumSeptember 9, 2025 | globenewswire.comParkman Healthcare Partners LLC Invests $1.43 Million in Upstream Bio, Inc. $UPBSeptember 8, 2025 | marketbeat.com22,586 Shares in Upstream Bio, Inc. $UPB Bought by Nuveen LLCSeptember 8, 2025 | marketbeat.comUpstream Bio, Inc. - Special CallSeptember 7, 2025 | seekingalpha.comUpstream Bio, Inc. (UPB) Special Call - SlideshowSeptember 5, 2025 | seekingalpha.comUpstream Bio Shares Rise on Positive Data for Sinus-Disease TreatmentSeptember 3, 2025 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLFCR, UPB, SYRE, and SPRY Company DescriptionsLifecore Biomedical NASDAQ:LFCR$6.74 -0.11 (-1.61%) Closing price 10/7/2025 04:00 PM EasternExtended Trading$6.73 -0.01 (-0.21%) As of 07:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.ARS Pharmaceuticals NASDAQ:SPRY$10.33 +0.06 (+0.58%) Closing price 10/7/2025 04:00 PM EasternExtended Trading$10.23 -0.10 (-0.98%) As of 07:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.Spyre Therapeutics NASDAQ:SYRE$16.02 -0.65 (-3.90%) Closing price 10/7/2025 04:00 PM EasternExtended Trading$16.01 -0.01 (-0.06%) As of 10/7/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.Upstream Bio NASDAQ:UPB$18.67 -0.30 (-1.58%) Closing price 10/7/2025 04:00 PM EasternExtended Trading$18.58 -0.09 (-0.46%) As of 04:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming Sector 3 Dividend Aristocrats to Buy Before Year’s End The Juice Is Loose: Why Plug Power's Rally Is Just the Beginning Joby's Stock Rallies as Public Flights Validate Global Game Plan SharkNinja Is Flashing a Buy Signal the Market Is Ignoring Why Semtech Stock Is Rallying After Its NVIDIA Setback Marvell Insiders Buy Shares—Should Investors Follow Suit? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
